CED Cannabis Science Digest: 3 Early Therapeutic Cannabinoid Signals Worth Watching
This digest highlights three early therapeutic cannabinoid signals in Alzheimer's disease, pain-pathway drug design, and CBD use in sickle cell disease. These signals represent promising directions in cannabinoid therapeutic research. While not yet…
CED Cannabis Science Digest: 3 Public-Health Cannabis Signals Worth Watching
This digest highlights cannabis public health signals 2026, focusing on pregnancy outcomes, psychosis follow-up, and e-scooter road safety. These signals refine clinical counseling and screening. The evidence supports more specific risk conversations…
Cannabis Enforcement Policy Meetings: June 2026 Updates
This update covers cannabis enforcement policy meetings held in June 2026, highlighting key regulatory developments. These meetings influence enforcement actions and legal frameworks. Clinicians should stay informed about cannabis enforcement policy…
CED Cannabis Science Digest: 3 CBD and Cannabis Safety Signals Worth Watching
This digest highlights three verified CBD blood pressure safety signals alongside cannabis safety concerns in 2026 research. It covers oral CBD effects on blood pressure, CBD and alcohol co-use safety, and vaping-related lung risks. These signals provide…
This Week in Cannabis: Focus on Use Disorder Stigma and Research Barriers
This week’s roundup highlights cannabis use disorder stigma and research limitations at Michigan universities. The focus includes emerging science on cognition and policy shifts. Cannabis use disorder stigma remains a key topic in ongoing cannabis…
Mixed Cannabis Industry Articles June 19 2026 Overview
This post reviews mixed cannabis industry articles June 19 2026, highlighting clinical relevance and regulatory impacts. It covers key developments in cannabis market trends and clinical updates. Stay informed on evolving cannabis industry insights for…
CED Cannabis Science Digest: 3 Cannabis Use, Cognition, and Policy Signals Worth Watching
This digest highlights cannabis cognition after cessation alongside young-adult use and policy signals. It preserves three verified lower-certainty cannabis signals worth watching. These insights offer valuable context for clinicians and public health.
GLP-1 and Cannabis Use Disorder: The BMJ Study Explained
A BMJ cohort study of 606,434 veterans found GLP-1 drugs reduced cannabis use disorder risk by 14% and SUD-related deaths by 50%. Full clinical breakdown.
CED Cannabis Science Digest: 3 Behavior and Safety Signals Worth Watching
No fresh human clinical-trial-level cannabis paper cleared the lead threshold on June 19, 2026, but three verified cannabis behavior safety signals were still worth preserving. These signals include stigma related to cannabis use disorder, driving…
CED Cannabis Science Digest: 3 Safety Signals Worth Watching
This digest highlights prenatal cannabis safety signals verified in 2026, focusing on exposure risks, inflammatory bowel disease evidence, and semisynthetic cannabinoids. These signals provide important counseling insights without overstating treatment…
